LOGO
LOGO

Intraday Alerts

Nurix Therapeutics Stock Climbs 11% Over Deal With Roche To Develop And Commercialize Bexobrutideg

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Stock of Nurix Therapeutics, Inc. (NRIX) is climbing around 11 percent in Monday morning trading after it signed a deal with Roche (RHHBY) to co-develop and co-commercialise bexobrutideg.

The company's shares are currently trading at $16.47 on the Nasdaq, up 11.00 percent. The stock opened at $16.67 and has climbed as high as $17.85 so far in today's session. Over the past year, it has traded in a range of $8.19 to $22.50.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

RELATED NEWS
Latest Updates on COVID-19